Drugs@FDA: FDA-Approved Drugs
New Drug Application (NDA): 214094
Company: BIOCRYST
Company: BIOCRYST
Drug Name | Active Ingredients | Strength | Dosage Form/Route | Marketing Status | TE Code | RLD | RS |
---|---|---|---|---|---|---|---|
ORLADEYO | BEROTRALSTAT HYDROCHLORIDE | EQ 110MG BASE | CAPSULE;ORAL | Prescription | None | Yes | No |
ORLADEYO | BEROTRALSTAT HYDROCHLORIDE | EQ 150MG BASE | CAPSULE;ORAL | Prescription | None | Yes | Yes |
Original Approvals or Tentative Approvals
Action Date | Submission | Action Type | Submission Classification | Review Priority; Orphan Status | Letters, Reviews, Labels, Patient Package Insert | Notes | Url |
---|---|---|---|---|---|---|---|
12/03/2020 | ORIG-1 | Approval | Type 1 - New Molecular Entity | STANDARD; Orphan |
Label (PDF)
Letter (PDF) Review |
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/214094s000lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2020/214094Orig1s000ltr.pdf https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/214094Orig1s000TOC.cfm |
Supplements
Action Date | Submission | Supplement Categories or Approval Type | Letters, Reviews, Labels, Patient Package Insert | Note | Url |
---|---|---|---|---|---|
10/21/2024 | SUPPL-3 | Labeling-Package Insert |
Label (PDF)
Letter (PDF) |
https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/214094s003lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2024/214094Orig1s003ltr.pdf | |
11/21/2023 | SUPPL-2 | Labeling-Package Insert |
Label (PDF)
Letter (PDF) |
https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/214094s002lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2023/214094Orig1s002ltr.pdf |
Action Date | Submission | Supplement Categories or Approval Type | Letters, Reviews, Labels, Patient Package Insert |
Note | Url |
---|---|---|---|---|---|
10/21/2024 | SUPPL-3 | Labeling-Package Insert | Label (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/214094s003lbl.pdf | |
11/21/2023 | SUPPL-2 | Labeling-Package Insert | Label (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/214094s002lbl.pdf | |
12/03/2020 | ORIG-1 | Approval | Label (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/214094s000lbl.pdf |